Upstream Bio, Inc. (UPB) shares tumbled 51.55 percent, falling $13.48 to $14.33 on Wednesday, even after the company announced positive top-line results from its Phase 2 VALIANT clinical trial evaluating verekitug in adults with severe asthma.
The clinical-stage biotechnology company said the study assessed the safety and efficacy of verekitug, an antagonist targeting the receptor for thymic stromal lymphopoietin, in patients with severe respiratory disease.
The stock is currently trading at $14.98, down from a previous close of $27.81. Shares opened at $19.00 and have traded between $15.30 and $20.00 during the session on the Nasdaq. The last bid was $14.39 for 200 shares, while the ask stood at $19.66 for 200 shares. Trading volume reached about 2.79 million shares, significantly above the average volume of about 0.59 million.
Upstream Bio shares have traded within a 52-week range of $5.14 to $33.68.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.